Metabolism alterations accompany the invasive phenotype of melanoma cells resistant to BRAF/MEK inhibitors.

doi:10.1016/j.bbamcr.2026.120205

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Metabolism alterations accompany the invasive phenotype of melanoma cells resistant to BRAF/MEK inhibitors.

Biochimica et biophysica acta. Molecular cell research - 1 Oct 2026

Kot Magdalena, Simiczyjew Aleksandra, Pietraszek-Gremplewicz Katarzyna, Majkowski Michał, Ziętek Marcin, Matkowski Rafał, Nowak Dorota

Abstract excerpt

Mutations in the BRAF (B-raf serine-threonine-protein kinase) gene occur in the majority of melanoma patients and significantly contribute to the progression of the disease. One of the most commonly used methods for treating melanoma is the use of BRAF and MEK (mitogen-activated protein kinase kinase) inhibitors. Unfortunately, resistance to treatment quickly develops in most patients. Therefore, an exhaustive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Drug Resistance, Neoplasm
Share to Glycolysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Invasiveness

Share to Piperidines

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Open in PubMed

Identifiers

PMID: 42567454
DOI: 10.1016/j.bbamcr.2026.120205

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.